GENETIC TECHNOLOGIES LIMITED - Announcements

Market Cap $15.86M Add to my watchlist

Technology Scientific & Technical Instruments

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

GTG	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	331.33KB	Share
GTG	Change in substantial holding		24/04/24	483.53KB	Share
GTG	Notification regarding unquoted securities - GTG		23/04/24	14.55KB	Share
GTG	Prospectus Supplement	PRICE SENSITIVE	23/04/24	453.09KB	Share
GTG	GTG announces closing of US$2M Registered Direct Offering		23/04/24	96.03KB	Share
GTG	S708A Cleansing Notice		22/04/24	87KB	Share
GTG	Application for quotation of securities - GTG		22/04/24	15.62KB	Share
GTG	Proposed issue of securities - GTG		22/04/24	15.96KB	Share
GTG	Proposed issue of securities - GTG		19/04/24	16.45KB	Share
GTG	GTG announces US$2 Million Registered Direct Offering	PRICE SENSITIVE	19/04/24	95.75KB	Share
GTG	GTG Announces New Precision Oncology Tests	PRICE SENSITIVE	17/04/24	136.64KB	Share
GTG	GTG to pilot GeneType in Breast Screen centres across the US	PRICE SENSITIVE	11/04/24	144.61KB	Share
GTG	Business Update April 2024		10/04/24	2.97MB	Share
GTG	GTG announces launch of Know Your Risk event		08/04/24	108.58KB	Share
GTG	GTG Secures Short Term Loan Facility with Radium Capital		26/03/24	245.13KB	Share
GTG	Appointment of CFO & Company Secretary		25/03/24	66.4KB	Share
GTG	GTG to develop Worlds Most Advanced Comprehensive Risk Test	PRICE SENSITIVE	22/03/24	212.98KB	Share
GTG	Results of Extraordinary General Meeting		20/03/24	166.65KB	Share
GTG	Appendix 3Y - Change of Director's Interest Notice		07/03/24	265.4KB	Share
GTG	GTG to launch U.S. Customer Digital Media Sales Campaign		28/02/24	155.46KB	Share
GTG	Appendix 4D & Half-year Financial Report - 31 December 2023	PRICE SENSITIVE	23/02/24	1.15MB	Share
GTG	Notice of Extraordinary General Meeting & Sample Proxy Form		20/02/24	629.46KB	Share
GTG	Board Renewal and Resignation of Director		15/02/24	316.2KB	Share
GTG	Notification of cessation of securities - GTG		07/02/24	12.65KB	Share
GTG	Appendix 4C & Quarterly Business Update December 2023	PRICE SENSITIVE	31/01/24	368.18KB	Share
GTG	Resignation of Chief Financial Officer & Company Secretary		08/01/24	107.87KB	Share
GTG	Notification of cessation of securities - GTG		28/12/23	21.44KB	Share
GTG	Notification regarding unquoted securities - GTG		28/12/23	23.55KB	Share
GTG	4xAppendix 3Y-Share Consolidation & Performance Right Expiry		27/12/23	626.1KB	Share
GTG	Receipt of the R & D Tax Incentive Refund	PRICE SENSITIVE	18/12/23	74.93KB	Share
GTG	NASDAQ Confirms First Trading Date of Consolidated ADS		07/12/23	88.88KB	Share
GTG	Update - Consolidation/Split - GTG	PRICE SENSITIVE	07/12/23	25.58KB	Share
GTG	Updated Share Consolidation Timetable	PRICE SENSITIVE	06/12/23	93.07KB	Share
GTG	Update - Consolidation/Split - GTG		06/12/23	25.58KB	Share
GTG	Notification of cessation of securities - GTG		04/12/23	21.51KB	Share
GTG	Change to Share Consolidation Timetable		01/12/23	88.04KB	Share
GTG	Update - Consolidation/Split - GTG	PRICE SENSITIVE	01/12/23	25.57KB	Share
GTG	Results of 2023 AGM		22/11/23	282.15KB	Share
GTG	2023 AGM Presentation	PRICE SENSITIVE	22/11/23	4.05MB	Share
GTG	Proposed Change to Timetable for Resolution 5		21/11/23	83.98KB	Share
GTG	Consolidation/Split - GTG	PRICE SENSITIVE	21/11/23	25.36KB	Share
GTG	Appendix 4C and Quarterly Activities Report - September 2023	PRICE SENSITIVE	30/10/23	272.91KB	Share
GTG	Notice of Annual General Meeting and Proxy Form		20/10/23	468.25KB	Share
GTG	Date of AGM and Closing Date for Director Nominations		29/09/23	73.64KB	Share
GTG	GTG & Gold Coast Hospital Announce Precision Medicine Pilot	PRICE SENSITIVE	28/09/23	124.64KB	Share
GTG	MRFF Grant Names GTG as Sole Industry Partner	PRICE SENSITIVE	11/09/23	135.66KB	Share
GTG	geneType Granted Approval for 3 New Diseases in Australia	PRICE SENSITIVE	11/09/23	130.36KB	Share
GTG	Annual Results Momentum Building on our Commercial Plans	PRICE SENSITIVE	31/08/23	107.73KB	Share
GTG	Appendix 4G and Corporate Governance Statement		31/08/23	460.39KB	Share
GTG	2023 Annual Report and Appendix 4E	PRICE SENSITIVE	31/08/23	8.14MB	Share
GTG	Change in substantial holding		17/08/23	1.43MB	Share
GTG	Updated Investor Presentation - August 2023	PRICE SENSITIVE	09/08/23	2.3MB	Share
GTG	Investor Webinar Quarterly Business Update June 2023		03/08/23	144.62KB	Share
GTG	Appendix 4C and Quarterly Activities Report - June 2023	PRICE SENSITIVE	28/07/23	569.19KB	Share
GTG	Notification of cessation of securities - GTG		17/07/23	21.51KB	Share
GTG	Notification of cessation of securities - GTG		10/05/23	21.51KB	Share
GTG	Updated Investor Presentation and Investor Webinar		02/05/23	3.35MB	Share
GTG	Publication Validates geneType for Melanoma Risk Assessment	PRICE SENSITIVE	28/04/23	215.09KB	Share
GTG	Appendix 4C & Quarterly Activities Report - March 2023	PRICE SENSITIVE	27/04/23	442.48KB	Share
GTG	Change in substantial holding		24/04/23	336.28KB	Share
GTG	Publication Validates geneType Prostate Cancer Risk Test	PRICE SENSITIVE	19/04/23	180.36KB	Share
GTG	GeneType MultiTest Panel Expanded Inclusion of New Diseases	PRICE SENSITIVE	27/03/23	273.91KB	Share
GTG	Response to ASX Query	PRICE SENSITIVE	17/03/23	228.9KB	Share
GTG	Further Study Validates geneType Breast Cancer Risk Test	PRICE SENSITIVE	13/03/23	206.16KB	Share
GTG	Notification of cessation of securities - GTG		07/03/23	21.55KB	Share
GTG	Change in substantial holding		01/03/23	1.52MB	Share
GTG	Half Year Financial Results Investor Webinar Presentation		28/02/23	2.26MB	Share
GTG	Appendix 4D & Half-year Financial Report December 2022	PRICE SENSITIVE	27/02/23	790.07KB	Share
GTG	2023 Half-year Financial Results Investor Webinar		24/02/23	143.17KB	Share
GTG	Notification of cessation of securities - GTG		17/02/23	21.52KB	Share
GTG	Receipt of R&D Tax Incentive Refund for geneType Multi Test	PRICE SENSITIVE	17/02/23	138.57KB	Share
GTG	Publication Highlights geneType Outperforms Current Models	PRICE SENSITIVE	09/02/23	245.83KB	Share
GTG	Business Update - February 2023	PRICE SENSITIVE	09/02/23	3.02MB	Share
GTG	Change in substantial holding		09/02/23	1.49MB	Share
GTG	Prospectus Supplement	PRICE SENSITIVE	08/02/23	392.42KB	Share
GTG	GTG Announces Closing of US$5M Registered Direct Offering		08/02/23	153.3KB	Share
GTG	Section 708A - Cleansing Notice		07/02/23	394.07KB	Share
GTG	Application for quotation of securities - GTG		07/02/23	24.65KB	Share
GTG	Proposed issue of securities - GTG		07/02/23	24.98KB	Share
GTG	Supplementary Announcement - Comprehensive Risk Test	PRICE SENSITIVE	06/02/23	196.21KB	Share
GTG	Proposed issue of securities - GTG		06/02/23	25.56KB	Share
GTG	Genetic Technologies Announces US$5M Registered Direct Offer	PRICE SENSITIVE	06/02/23	153.29KB	Share
GTG	World First Comprehensive Risk Test-Breast & Ovarian Cancer	PRICE SENSITIVE	03/02/23	165.17KB	Share
GTG	Appendix 3Y Change of Directors Interest Notice		02/02/23	295.06KB	Share
GTG	GTG to form Strategic Alliance with global leader QIAGEN	PRICE SENSITIVE	01/02/23	161.99KB	Share
GTG	Appendix 4C and Quarterly Business Update December 2022	PRICE SENSITIVE	30/01/23	320.17KB	Share
GTG	Colorectal Cancer Model Presented at ASCOGI Cancer Symposium	PRICE SENSITIVE	24/01/23	180.63KB	Share
GTG	Notification of cessation of securities - GTG		11/01/23	23.65KB	Share
GTG	Appendix 3Y - Lindsay Wakefield		11/01/23	437.06KB	Share
GTG	Change in substantial holding		07/12/22	2.23MB	Share
GTG	GeneType Published in PLUS ONE for CVD & Type 2 Diabetes	PRICE SENSITIVE	06/12/22	195.52KB	Share
GTG	Results of AGM		28/11/22	316.71KB	Share
GTG	AGM Presentation and Chairman's Address	PRICE SENSITIVE	28/11/22	2.56MB	Share
GTG	GTG Webinar on Risk Assessment Tests for Serious Disease		10/11/22	163.08KB	Share
GTG	Notification of cessation of securities - GTG		09/11/22	21.62KB	Share
GTG	Genetype for Ovarian Cancer published in European Journal	PRICE SENSITIVE	09/11/22	218.31KB	Share
GTG	Change of Director's Interest Notice		09/11/22	497.25KB	Share
GTG	Genetic Technologies Investor Presentation Webinar		04/11/22	2.05MB	Share
GTG	Notice of Annual General Meeting/Proxy Form		27/10/22	562KB	Share
GTG	Genetic Technologies AusBioInvest Presentation		27/10/22	2.06MB	Share

GTG Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	331.33KB	Share
GTG Change in substantial holding
24/04/24		483.53KB	Share
GTG Notification regarding unquoted securities - GTG
23/04/24		14.55KB	Share
GTG Prospectus Supplement
23/04/24	PRICE SENSITIVE	453.09KB	Share
GTG GTG announces closing of US$2M Registered Direct Offering
23/04/24		96.03KB	Share
GTG S708A Cleansing Notice
22/04/24		87KB	Share
GTG Application for quotation of securities - GTG
22/04/24		15.62KB	Share
GTG Proposed issue of securities - GTG
22/04/24		15.96KB	Share
GTG Proposed issue of securities - GTG
19/04/24		16.45KB	Share
GTG GTG announces US$2 Million Registered Direct Offering
19/04/24	PRICE SENSITIVE	95.75KB	Share
GTG GTG Announces New Precision Oncology Tests
17/04/24	PRICE SENSITIVE	136.64KB	Share
GTG GTG to pilot GeneType in Breast Screen centres across the US
11/04/24	PRICE SENSITIVE	144.61KB	Share
GTG Business Update April 2024
10/04/24		2.97MB	Share
GTG GTG announces launch of Know Your Risk event
08/04/24		108.58KB	Share
GTG GTG Secures Short Term Loan Facility with Radium Capital
26/03/24		245.13KB	Share
GTG Appointment of CFO & Company Secretary
25/03/24		66.4KB	Share
GTG GTG to develop Worlds Most Advanced Comprehensive Risk Test
22/03/24	PRICE SENSITIVE	212.98KB	Share
GTG Results of Extraordinary General Meeting
20/03/24		166.65KB	Share
GTG Appendix 3Y - Change of Director's Interest Notice
07/03/24		265.4KB	Share
GTG GTG to launch U.S. Customer Digital Media Sales Campaign
28/02/24		155.46KB	Share
GTG Appendix 4D & Half-year Financial Report - 31 December 2023
23/02/24	PRICE SENSITIVE	1.15MB	Share
GTG Notice of Extraordinary General Meeting & Sample Proxy Form
20/02/24		629.46KB	Share
GTG Board Renewal and Resignation of Director
15/02/24		316.2KB	Share
GTG Notification of cessation of securities - GTG
07/02/24		12.65KB	Share
GTG Appendix 4C & Quarterly Business Update December 2023
31/01/24	PRICE SENSITIVE	368.18KB	Share
GTG Resignation of Chief Financial Officer & Company Secretary
08/01/24		107.87KB	Share
GTG Notification of cessation of securities - GTG
28/12/23		21.44KB	Share
GTG Notification regarding unquoted securities - GTG
28/12/23		23.55KB	Share
GTG 4xAppendix 3Y-Share Consolidation & Performance Right Expiry
27/12/23		626.1KB	Share
GTG Receipt of the R & D Tax Incentive Refund
18/12/23	PRICE SENSITIVE	74.93KB	Share
GTG NASDAQ Confirms First Trading Date of Consolidated ADS
07/12/23		88.88KB	Share
GTG Update - Consolidation/Split - GTG
07/12/23	PRICE SENSITIVE	25.58KB	Share
GTG Updated Share Consolidation Timetable
06/12/23	PRICE SENSITIVE	93.07KB	Share
GTG Update - Consolidation/Split - GTG
06/12/23		25.58KB	Share
GTG Notification of cessation of securities - GTG
04/12/23		21.51KB	Share
GTG Change to Share Consolidation Timetable
01/12/23		88.04KB	Share
GTG Update - Consolidation/Split - GTG
01/12/23	PRICE SENSITIVE	25.57KB	Share
GTG Results of 2023 AGM
22/11/23		282.15KB	Share
GTG 2023 AGM Presentation
22/11/23	PRICE SENSITIVE	4.05MB	Share
GTG Proposed Change to Timetable for Resolution 5
21/11/23		83.98KB	Share
GTG Consolidation/Split - GTG
21/11/23	PRICE SENSITIVE	25.36KB	Share
GTG Appendix 4C and Quarterly Activities Report - September 2023
30/10/23	PRICE SENSITIVE	272.91KB	Share
GTG Notice of Annual General Meeting and Proxy Form
20/10/23		468.25KB	Share
GTG Date of AGM and Closing Date for Director Nominations
29/09/23		73.64KB	Share
GTG GTG & Gold Coast Hospital Announce Precision Medicine Pilot
28/09/23	PRICE SENSITIVE	124.64KB	Share
GTG MRFF Grant Names GTG as Sole Industry Partner
11/09/23	PRICE SENSITIVE	135.66KB	Share
GTG geneType Granted Approval for 3 New Diseases in Australia
11/09/23	PRICE SENSITIVE	130.36KB	Share
GTG Annual Results Momentum Building on our Commercial Plans
31/08/23	PRICE SENSITIVE	107.73KB	Share
GTG Appendix 4G and Corporate Governance Statement
31/08/23		460.39KB	Share
GTG 2023 Annual Report and Appendix 4E
31/08/23	PRICE SENSITIVE	8.14MB	Share
GTG Change in substantial holding
17/08/23		1.43MB	Share
GTG Updated Investor Presentation - August 2023
09/08/23	PRICE SENSITIVE	2.3MB	Share
GTG Investor Webinar Quarterly Business Update June 2023
03/08/23		144.62KB	Share
GTG Appendix 4C and Quarterly Activities Report - June 2023
28/07/23	PRICE SENSITIVE	569.19KB	Share
GTG Notification of cessation of securities - GTG
17/07/23		21.51KB	Share
GTG Notification of cessation of securities - GTG
10/05/23		21.51KB	Share
GTG Updated Investor Presentation and Investor Webinar
02/05/23		3.35MB	Share
GTG Publication Validates geneType for Melanoma Risk Assessment
28/04/23	PRICE SENSITIVE	215.09KB	Share
GTG Appendix 4C & Quarterly Activities Report - March 2023
27/04/23	PRICE SENSITIVE	442.48KB	Share
GTG Change in substantial holding
24/04/23		336.28KB	Share
GTG Publication Validates geneType Prostate Cancer Risk Test
19/04/23	PRICE SENSITIVE	180.36KB	Share
GTG GeneType MultiTest Panel Expanded Inclusion of New Diseases
27/03/23	PRICE SENSITIVE	273.91KB	Share
GTG Response to ASX Query
17/03/23	PRICE SENSITIVE	228.9KB	Share
GTG Further Study Validates geneType Breast Cancer Risk Test
13/03/23	PRICE SENSITIVE	206.16KB	Share
GTG Notification of cessation of securities - GTG
07/03/23		21.55KB	Share
GTG Change in substantial holding
01/03/23		1.52MB	Share
GTG Half Year Financial Results Investor Webinar Presentation
28/02/23		2.26MB	Share
GTG Appendix 4D & Half-year Financial Report December 2022
27/02/23	PRICE SENSITIVE	790.07KB	Share
GTG 2023 Half-year Financial Results Investor Webinar
24/02/23		143.17KB	Share
GTG Notification of cessation of securities - GTG
17/02/23		21.52KB	Share
GTG Receipt of R&D Tax Incentive Refund for geneType Multi Test
17/02/23	PRICE SENSITIVE	138.57KB	Share
GTG Publication Highlights geneType Outperforms Current Models
09/02/23	PRICE SENSITIVE	245.83KB	Share
GTG Business Update - February 2023
09/02/23	PRICE SENSITIVE	3.02MB	Share
GTG Change in substantial holding
09/02/23		1.49MB	Share
GTG Prospectus Supplement
08/02/23	PRICE SENSITIVE	392.42KB	Share
GTG GTG Announces Closing of US$5M Registered Direct Offering
08/02/23		153.3KB	Share
GTG Section 708A - Cleansing Notice
07/02/23		394.07KB	Share
GTG Application for quotation of securities - GTG
07/02/23		24.65KB	Share
GTG Proposed issue of securities - GTG
07/02/23		24.98KB	Share
GTG Supplementary Announcement - Comprehensive Risk Test
06/02/23	PRICE SENSITIVE	196.21KB	Share
GTG Proposed issue of securities - GTG
06/02/23		25.56KB	Share
GTG Genetic Technologies Announces US$5M Registered Direct Offer
06/02/23	PRICE SENSITIVE	153.29KB	Share
GTG World First Comprehensive Risk Test-Breast & Ovarian Cancer
03/02/23	PRICE SENSITIVE	165.17KB	Share
GTG Appendix 3Y Change of Directors Interest Notice
02/02/23		295.06KB	Share
GTG GTG to form Strategic Alliance with global leader QIAGEN
01/02/23	PRICE SENSITIVE	161.99KB	Share
GTG Appendix 4C and Quarterly Business Update December 2022
30/01/23	PRICE SENSITIVE	320.17KB	Share
GTG Colorectal Cancer Model Presented at ASCOGI Cancer Symposium
24/01/23	PRICE SENSITIVE	180.63KB	Share
GTG Notification of cessation of securities - GTG
11/01/23		23.65KB	Share
GTG Appendix 3Y - Lindsay Wakefield
11/01/23		437.06KB	Share
GTG Change in substantial holding
07/12/22		2.23MB	Share
GTG GeneType Published in PLUS ONE for CVD & Type 2 Diabetes
06/12/22	PRICE SENSITIVE	195.52KB	Share
GTG Results of AGM
28/11/22		316.71KB	Share
GTG AGM Presentation and Chairman's Address
28/11/22	PRICE SENSITIVE	2.56MB	Share
GTG GTG Webinar on Risk Assessment Tests for Serious Disease
10/11/22		163.08KB	Share
GTG Notification of cessation of securities - GTG
09/11/22		21.62KB	Share
GTG Genetype for Ovarian Cancer published in European Journal
09/11/22	PRICE SENSITIVE	218.31KB	Share
GTG Change of Director's Interest Notice
09/11/22		497.25KB	Share
GTG Genetic Technologies Investor Presentation Webinar
04/11/22		2.05MB	Share
GTG Notice of Annual General Meeting/Proxy Form
27/10/22		562KB	Share
GTG Genetic Technologies AusBioInvest Presentation
27/10/22		2.06MB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 12.0¢		Change 0.000(0.00%)		Mkt cap ! $15.86M

Open	High	Low	Value	Volume
12.0¢	12.0¢	11.0¢	$4.415K	36.83K

Buyers (Bids)

No.	Vol.	Price($)
1	17530	11.0¢

Sellers (Offers)

Price($)	Vol.	No.
12.0¢	4879	2

View Market Depth

No.	Vol.	Price($)
1	17530	0.110
6	269044	0.105
12	250878	0.100
1	49000	0.097
1	11000	0.096

Price($)	Vol.	No.
0.120	4879	2
0.125	32601	2
0.130	42000	2
0.135	34167	2
0.140	22500	1

Last trade - 16.10pm 03/05/2024 (20 minute delay)

GTG (ASX) Chart

GENETIC TECHNOLOGIES LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories